Publications by authors named "R CERQUA"
Article Synopsis
- The study aims to evaluate the risk of multiple sclerosis (MS) reactivation during and after pregnancy in women treated with natalizumab (NTZ), comparing those who continued treatment (LONG_EXP) with those who interrupted it before or shortly after conception (NO_EXP, SHORT_EXP).
- Results showed that women who continued NTZ during pregnancy had a significantly lower annualized relapse rate and fewer gadolinium-enhancing lesions than those who interrupted treatment.
- Newborns' health outcomes were similar across the groups, with no significant differences in weight, length, or head circumference, although there was a slight incidence of anemia in the LONG_EXP group.
Gut-oriented interventions in patients with multiple sclerosis: fact or fiction?
Eur Rev Med Pharmacol Sci
February 2022
Objective: Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, disimmune disease of the central nervous system whose etiology and pathogenesis remain poorly understood, due to its complex and multifactorial nature. Evidence of a bidirectional connection linking the gut microbiome with the intestinal barrier and the immune system (the gut-brain axis) may have implications for the pathogenesis of inflammatory demyelinating diseases such as MS. This narrative review summarizes the evidence for the gut-brain axis involvement in the pathogenesis of MS and examines the role of gut-oriented interventions in MS.
View Article and Find Full Text PDFBackground And Purpose: Tumefactive multiple sclerosis (TuMS) (i.e., MS onset presenting with tumefactive demyelinating lesions [TDLs]) is a diagnostic and therapeutic challenge.
View Article and Find Full Text PDFCladribine vs other drugs in MS: Merging randomized trial with real-life data.
Neurol Neuroimmunol Neuroinflamm
November 2020
Objective: Cladribine tablets were tested against placebo in randomized controlled trials (RCTs). In this study, the effectiveness of cladribine vs other approved drugs in patients with relapsing-remitting MS (RRMS) was compared by matching RCT to observational data.
Methods: Data from the pivotal trial assessing cladribine tablets vs placebo (CLARITY) were propensity score matched to data from the Italian multicenter database i-MuST.
Long-term outcome in multiple sclerosis patients treated with fingolimod.
Mult Scler Relat Disord
October 2020
Background And Purpose: Ongoing disease activity during treatment has been associated to worse disability outcomes in patients with Multiple Sclerosis (MS). The aim of this study was to assess the 5-year response to fingolimod (FTY) treatment in patients with relapsing-remitting (RRMS) in a real-life setting.
Methods: We included RRMS patients who received FTY for at least 6 months and had a follow-up ≥ 60 months.